肿瘤细胞治疗研究
英文原题：Programmed death ligand-1 (PD-L1) expression in serous ovarian carcinoma with clinicopathological associations.
Programmed death ligand-1 (PD-L1) expression in serous ovarian carcinoma with clinicopathological associations.
方法 在印度新德里一家三级医疗中心进行了一项为期一年的30例回顾性研究。
背景与目的 程序性死亡-1配体（PD-L1）在浆液性卵巢癌中的表达 prevalence 及其意义尚未明确。本研究旨在通过免疫组织化学（IHC）在全组织切片中评估浆液性卵巢癌的PD-L1表达，并将其表达与相关临床病理特征进行关联分析。方法 在印度新德里一家三级医疗中心进行了一项为期一年的30例回顾性研究。所有病例均通过HandE染色进行复核，并使用PD-L1（E1L3N®）XP®兔单克隆抗体在poly-L-赖氨酸包被的玻片上手动进行PD-L1的IHC检测。记录并分析了额外的临床形态学数据。结果 基于1% cut-off的联合阳性评分（CPS），33%的病例中观察到PD-L1表达。PD-L1表达与较高的FIGO分期和TIL（肿瘤浸润淋巴细胞）（TILs）的存在呈正相关（P=0.029）。解读与结论 PD-L1可能作为浆液性卵巢癌的潜在预后标志物。其表达有助于识别可能从基于PD-L1的靶向治疗中获益的患者，并有助于更好地理解卵巢癌的生物学行为。
Background and objectives The prevalence and significance of programmed death-1 ligand (PD-L1) expression in serous ovarian carcinoma are not well established. This study aimed to evaluate PD-L1 expression using immunohistochemistry (IHC) in whole tissue sections of serous ovarian carcinoma and to correlate its expression with relevant clinicopathological characteristics. Methods A retrospective study of 30 cases was conducted at a tertiary care centre in New Delhi, India, over one yr. All cases were reviewed using HandE staining, and IHC for PD-L1 was performed manually on poly-L-lysine-coated slides using the PD-L1 (E1L3N®) XP® Rabbit monoclonal antibody. Additional clinicomorphological data were recorded and analysed. Results Based on the combined positive score (CPS) with a 1% cutoff, PD-L1 expression was observed in 33% of cases. PD-L1 expression demonstrated a positive correlation with higher FIGO stage and the presence of tumour-infiltrating lymphocytes (TILs) (P=0.029). Interpretation and conclusion PD-L1 may serve as a potential prognostic marker in serous ovarian carcinoma. Its expression could help identify patients who may benefit from targeted PD-L1-based therapies and contributes to a better understanding of the biological behaviour of ovarian carcinoma.
MEMBER ACCOUNT
登录成功会直接打开下一页。
